Biological Availability Clinical Trial
Official title:
CaDoBio (Calcium Dobesilate Bioavailability): a Bioavailability and Pharmacokinetics Research Project to Measure the Concentrations of Calcium Dobesilate (Doxium®) in the Nasal Mucosal Tissue, Saliva and Blood of Treated Patients
Calcium dobesilate (CaD) has been shown to have potential antiviral effects, mediated via its interaction with the heparansulfate (HS) binding site of the viral SARS-CoV-2 spike protein (direct action), necessary for interation with the ACE-2 receptor on human cells. Preliminary pre-clinical results using viral pseudotyped particles demonstrated that CaD reduces the uptake of SARS-CoV-2 spike protein in cultured endothelial cells by more than 50%. Moreover, CaD is a well-established vasoactive and angioprotective drug improving endothelial dysfunction with a good tolerability profile. CaD strengthens vessels integrity and improves blood flow by acting on multiple parameters, like cytokines levels and signaling by FGF and VEGF. All these parameters may be dysregulated at some stage of Covid-19 pathological evolution, and acting on these could potentially reduce the progression toward severe disease. Based on these data, we hypothesize that CaD could be used as an early treatment for SARS-CoV-2 positive outpatients. However, bioavailability data and pharmacokinetics of CaD are not well known, outside of old data on animal models. Being able to show that the drug is present in nasal mucosae and saliva, where the virus is likely to start the infection of the host, would be a first step before studying a possible effect on the disease course on infected patients. Therefore this project plans to include between 6 and 10 patients, treated with CaD, for whom different nasal, saliva and blood sample will be taken at different timepoints before and after the daily dose of the treatment. Samples will be then analysed to detect and quantify the presence of CaD.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05544786 -
Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
|
Phase 1 | |
| Completed |
NCT04744233 -
Bioavailability of Carotenoids From Orange Juice in a Cross-over Study in Healthy Subjects.
|
N/A | |
| Completed |
NCT05561075 -
Oral Bioavailability of Pterostilbene Cocrystal Compared to Its Free Form (BIOPTERO)
|
N/A | |
| Completed |
NCT03873909 -
Bioavailability of Carotenoids Present in Mamey Sapote (Pouteria Sapota (Jacq.) H. E. Moore & Stearn) Fruit
|
N/A | |
| Completed |
NCT03353857 -
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
|
Phase 1 | |
| Completed |
NCT05121506 -
A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01267201 -
A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form
|
Phase 1 | |
| Completed |
NCT02538393 -
Relative Bioavailability of Sorafenib Tablet for Oral Suspension
|
Phase 1 | |
| Completed |
NCT05116982 -
Effect of Three Silicon Based Food Supplements on the Urinary Excretion of Aluminum and Other Metals (SILIAL)
|
N/A | |
| Completed |
NCT04207372 -
Protein Digestibility of Whey and Zein.
|
N/A | |
| Completed |
NCT01853800 -
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
|
Phase 1 | |
| Completed |
NCT00714584 -
Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04876261 -
Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements
|
N/A | |
| Completed |
NCT03886597 -
Nutritional Intervention With Table Olives in Healthy Volunteers
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06289140 -
Oral Bioavailability of a New Formulation of Pterostilbene Cocrystal in Comparison With Its Free Form (BIOPTERO2)
|
N/A | |
| Completed |
NCT05439408 -
Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions
|
Phase 1 | |
| Completed |
NCT03951025 -
Study of the Bioavailability of a Food Supplement Rich in Melatonin Administered Sublingually and Orally (MELATONIN)
|
Phase 2 | |
| Completed |
NCT03984916 -
Study of the Bioavailability of Three Hesperidin Extracts.
|
N/A | |
| Completed |
NCT02966704 -
Stable Isotope Method to Assess Dietary Protein Quality
|
N/A | |
| Completed |
NCT02847117 -
Bioavailability of the Microconstituents of Natural Chios Mastiha in Healthy Adults.
|
N/A |